MediciNova is preparing for regulatory discussions regarding its MN-166 compound, which is part of the COMBAT-ALS Phase 2/3 trial, and has received a $22 million grant from the NIH.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MediciNova is preparing for regulatory discussions regarding its MN-166 compound, which is part of the COMBAT-ALS Phase 2/3 trial, and has received a $22 million grant from the NIH.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
MediciNova (United States)
company in La Jolla, United States
Nothing else this week.
-
National Institute of Health
medical research institute, Pakistani government body
Nothing else this week.
Related events
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
- A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
- NewcelX Ltd. advanced its IND-enabling work for a Phase 1/2a trial and held a successful Type B Pre-IND meeting with the FDA.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
Coverage
Newest first; wire copies grouped- GlobeNewswireMediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial